Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: IPOs
Stocks: JNJ, SNOW

Is the Grail IPO Worth Investing In?

By Mike Stenger, Associate Editor, Money Morning • September 18, 2020

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

The S&P 500 lost 31% in March. The IPO market saw a huge slump in the ensuing months. There was little confidence in the public market.

But certain players in the health sector did not hurt the same. In fact, tech and health stocks seemed more stable with a work-from-home trend and a push for coronavirus vaccines.

While these sectors got a lift from this year's events, they didn't need it.

There will always be companies innovating in tech and health, despite any lockdown scenario.

Grail is one of those companies. That's why, in a year of scant IPOs, this innovative biotech is one of a handful that have come out announcing their IPO underway.

Sorry; this signup opportunity has ended.

Grail joins a flood of other tech IPO announcements this fall, including Snowflake, Sumo Logic, Unity, Asana, JFrog, and Palantir.

The Menlo Park, CA company announced its IPO last Wednesday.

It's at the cutting edge of science. But does that mean you should invest in the Grail IPO?

Here are some things to keep in mind before you do...

What Is Grail?

Liquid biopsies are a fairly new innovation in cancer screening. This is a way of checking for cancer without actually having to obtain any of the tumor tissue.

Tumors tend to shed DNA into the bloodstream. So an alternative is to simply draw blood for testing.

Grail is one of several biotech startups that have delivered a liquid biopsy tool. It's called Galleri.

What makes Galleri so intriguing is the fact that it screens for multiple cancers. Other liquid biopsy startups out there screen for just one.

Three stocks every investor should consider owning today, and dozens of stocks to drop immediately. Click here...

Sign up for SMS so you never miss special events, exclusive offers, and weekly bonus trades.
With that, the Grail claims it could avert 39% of deaths from cancers that would otherwise kill in five years. It said in its filing that it could detect almost 70% of cancers resulting in death within five years at an early stage.

Its tests so far have detected more than 50 cancers, with a predictive value of 43% and 7,000 false positives per million. That's huge, because it even beats several single-cancer biopsies.

Grail is a spin-off of another biotech, Illumina, as of 2016. Right now, Grail's largest shareholders are still Illumina with 14.6% and Johnson & Johnson (NYSE: JNJ) with 7.6%.

Jeff Bezos and Bill Gates are also among this company's investors.

For many, that could seal the deal. But Grail could have a long way to go still ...

Is Grail Profitable?

Grail is not yet profitable. In fact, it has not had revenue since inception.

This is the catch with many biotech companies like Grail. It could be testing a product for years without anything to sell. The only thing you would have to go on is the company's progress through those tests.

That said, Grail is doing well in that department, an apparent leader in the liquid biopsy market.

The company is now gearing up to commercialize the Galleri product after extensive testing through 2021. By 2023, it hopes to have FDA approval, which would expose the product to 40 million more patients.

On top of that, the company reports around $686 million in cash as of June 30, and it plans to raise $100 million in the IPO. That should see it through the trials over that time.

If it continues to be successful, that's when the revenue will start piling up.

Early investing in biotech IPOs like these can have huge upside if you land the right one.

But there's also more risk...

Should You Buy Grail Stock at the IPO?

IPO investing is already risky enough as it is. The price is almost always driven up by market excitement leading up to the event. Often, that is followed by a crash.

For example, Snowflake Inc. (NYSE: SNOW) was one of the biggest software IPOs of all time. Despite all the excitement, it lost more than 8% in its first week of trading, going from $276 to $226.

The point is, it can be hard to discern when is the right time to buy into the stock.

Especially with biotech IPOs, you're not only predicting the success of a product in a market. You are also trying to predict whether the product will make it through a gauntlet of tests and bureaucratic measures.

Even with promising companies like Grail, this can be tricky. You can always stay up to date on the latest news releases to see how tests are going. But as long as the government is involved, it's hard to know whether it will go one way or another in the end.

Many investors will have faith in Grail's product. It's an exciting innovation, and investment from Bezos and Gates sure doesn't take away from that case.

But since IPOs can be volatile and Grail won't be releasing a product until the next year at the earliest, it makes sense to hold back. Let the price settle before buying in. You might even get to buy in at a lower price than on IPO day by waiting a few weeks.

And that's only if you're comfortable with the risk of investing in a biotech stock. If the company's products get approval and start raking in revenue, you could have a winner. But it not, you could wind up losing money.

As you await the Grail IPO, look for the stock ticker symbol GRAL.

If you're looking to profit even sooner, you can check out a few stocks that are already public...

Three Stocks Even Better Than GRAL

Chief Investment Strategist Shah Gilani just held his first-ever stock-picking lightning round event - running through more than 50 stocks to tell you if they are stocks to buy or stocks to sell.

Dozens are overpriced and overhyped - you should ditch them ASAP.

But Shah says THESE three stocks are "screaming buys."

All three are trading at a discount... they're under-the-radar companies most people haven't even heard of... and they have massive tailwinds ready to send their share prices into the stratosphere.

To get the company names, tickers, and price targets for Shah's picks, go here now.

Follow Money Morning onFacebook and Twitter.

Join the conversation. Click here to jump to comments…

Mike StengerMike Stenger

About the Author

Browse Mike's articles | View Mike's research services

Mike Stenger, Associate Editor forĀ Money MorningĀ at Money Map Press,Ā graduated from the Perdue School of Business at Salisbury University. He has combined his degree in Economics with an interest in emerging technologies by finding where tech and finance overlap. Today, he studies the cybersecurity sector, AI, streaming, and the Cloud.

… Read full bio

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments

Is the Grail IPO Worth Investing In?

Start the conversation

ByĀ MIKE STENGER,Ā Associate Editor,Ā Money Morning • September 18, 2020


Dear Red Alert Reader,

The S&P 500 lost 31% in March. The IPO market saw a huge slump in the ensuing months. There was little confidence in the public market.

But certain players in the health sector did not hurt the same. In fact, tech and health stocks seemed more stable with a work-from-home trend and a push for coronavirus vaccines.

While these sectors got a lift from this year’s events, they didn’t need it.

There will always be companies innovating in tech and health, despite any lockdown scenario.

LIVE: Six brand-new deal recommendations locked and loaded. Get the details.

Grail is one of those companies. That’s why, in a year of scant IPOs, this innovative biotech is one of a handful that have come out announcing their IPO underway.

Grail joins a flood of other tech IPO announcements this fall, including Snowflake, Sumo Logic, Unity, Asana, JFrog and Palantir.

The Menlo Park, CA company announced its IPO last Wednesday.

It’s at the cutting-edge of science. But does that mean you should invest in the Grail IPO?

Some things to keep in mind before you do…

What Is Grail?

Liquid biopsies are a fairly new innovation in cancer screening. This is a way of checking for cancer without actually having to obtain any of the tumor tissue.

Tumors tend to shed DNA into the bloodstream. So an alternative is to simply draw blood for testing.

Grail is one of several biotech startups that have delivered a liquid biopsy tool. It’s called Galleri.

What makes Galleri so intriguing is the fact that it screens for multiple cancers. Other liquid biopsy startups out there screen for just one.

With that, the Grail claims it could avert 39% of deaths from cancers that would otherwise kill in five years. It said in its filing that it could detect almost 70% of cancers resulting in death within five years at an early stage.

Their tests so far have detected more than 50 cancers, with a predictive value of 43% and 7,000 false positives per million. That’s huge, because it even beats several single-cancer biopsies.

Grail is a spinoff of another biotech, Illumina, as of 2016. Right now, Grail’s largest shareholders are still Illumina with 14.6% and Johnson & Johnson (NYSE: JNJ) with 7.6%.

Jeff Bezos and Bill Gates are also among this company’s investors.

For many, that could seal the deal. But Grail could have a long way to go still ...

Sign up for SMS so you never miss special events, exclusive offers, and weekly bonus trades.

Is Grail Profitable?

Grail is not yet profitable. In fact, they have not had revenue since inception.

This is the catch with many biotech companies like Grail. They could be testing a product for years without anything to sell. The only thing you would have to go on is the company’s progress through those tests.

That said, Grail is doing well in that department, an apparent leader in the liquid biopsy market.

The company is now gearing up to commercialize the Galleri product after extensive testing through 2021. By 2023, it hopes to have FDA approval, which would expose the product to 40 million more patients.


The 30-Something-Year-Old Projected to Be Worth Nearly $30M by Year’s End
He’s the most effective startup investor in America
. And now, he’s in YOUR corner, featuring SIX brand-new deal recommendationsĀ right off the bat. Take note: He’s currently sitting on a 95% success rate – anĀ unheard-ofĀ number for startup investors. To see him uncover his portfolio for the first time,Ā watch this now.


On top of that, the company reports around $686 million in cash as of June 30, and it plans to raise $100 million in the IPO. That should see it through the trials over that time.

If they continue to be successful, that’s when the revenue will start piling up.

Early investing in biotech IPOs like these can have huge upside if you land the right one.

But there’s also more risk…

Should You Buy Grail Stock at the IPO?

IPO investing is already risky enough as it is. The price is almost always driven up by market excitement leading up to the event. Often, that is followed by a crash.

For example, Snowflake (NASDAQ: SNOW) was one of the biggest software IPOs of all time. Despite all the excitement, it lost more than 8% in its first week of trading, going from $276 to $226.

The point is, it can be hard to discern when is the right time to buy into the stock.

Especially with biotech IPOs, you’re not only predicting the success of a product in a market. You are also trying to predict whether the product will make it through a gauntlet of tests and bureaucratic measures.

Even with promising companies like Grail, this can be tricky. You can always stay up to date on the latest news releases to see how tests are going. But as long as the government is involved, it’s hard to know whether it will go one way or another in the end.

Many investors will have faith in Grail’s product. It’s an exciting innovation, and investment from Bezos and Gates sure doesn’t take away from that case.

But since IPOs can be volatile and Grail won’t be releasing a product until the next year at the earliest, it makes sense to hold back. Let the price settle before buying in. You might even get to buy in at a lower price than on IPO day by waiting a few weeks.

And that’s only if you’re comfortable with the risk of investing in a biotech stock. If the company’s products get approval and start raking in revenue, you could have a winner. But it not, you could wind up losing money.

As you await the Grail IPO, look for the stock ticker symbol GRAL.

Six Pre-IPO Startups… Each with 100x Valuation Potential in the Next Few Years

In the VC world, demo days are typically reserved ONLY for multimillionaire investors… but that's not the case anymore.

We're hosting ourĀ ownĀ version of a "demo day" alongside NYC's greatest venture capitalist. During this unique deal analysis event, you'll meet six entrepreneurs, each showing folks how to invest in their early-stage startups and sharing all the details.

We believe any of these recommended companies could 100X their valuation in the next few years.

Join us to decide for yourself.

Join the conversation. Click here to jump to comments…

Red Alert StaffRed Alert Staff

About the Author

Browse Red Alert's articles | View Red Alert's research services
0 Comments
Inline Feedbacks
View all comments


Latest News

June 10, 2023 • By Garrett Baldwin

Postcards: The Costliest Disaster America's Facing is 100% Manmade

June 9, 2023 • By Nick Black

My Favorite Cryptocurrency to Buy This Weekend With up to 10X Potential

June 9, 2023 • By Shah Gilani

earnings
Pulling Back the Curtain on "The New Big Short"
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Flashpoint Trader Darknet Hyper Momentum Trader Alpha Accelerators Weekly Profit Cycles Brutus Alerts Resource Traders Alliance

Ā© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz